Anbio BiotechnologyNNNN
13F holders, Q4 2025 (December 31)5holders −5
0new positions
5sold out
$30.07avg. 13F price*
At the end of Q4 2025, 5 institutions reported holding Anbio Biotechnology Ltd. (NNNN) in their 13F filings, down 5 from Q3 2025. 0 opened new positions and 5 sold out. The largest holders were Geode Capital Management, LLC ($775K), UBS Group AG ($86K) and BNP Paribas Financial Markets ($30K).
- Company
- Anbio Biotechnology Ltd.
- CUSIP
- G0367B105
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q3 2025 → Q4 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 5 | $1.1M |
All 13F filers, Q3 2025 → Q4 2025: 1,889 shares bought and 40,454 shares sold, net −38,565 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 5 holders
| Geode Capital Management, LLC | 0.00% | No change | 25,763 | $775K |
| UBS Group AG | 0.00% | Add +196.8% | 2,849 | $86K |
| BNP Paribas Financial Markets | 0.00% | Reduce -58.7% | 1,000 | $30K |
| Wells Fargo & Company | 0.00% | No change | 100 | $3K |
| Morgan Stanley | 0.00% | Reduce -99.7% | 28 | $842 |
"% of holder's portfolio" is NNNN's weight in each manager's 13F, not the share of Anbio Biotechnology Ltd. the manager owns.